GSK (LON:GSK) Receives “Underweight” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their underweight rating on shares of GSK (LON:GSK) in a report released on Tuesday morning, MarketBeat.com reports.

Separately, Berenberg Bank dropped their price objective on shares of GSK from GBX 1,820 ($22.70) to GBX 1,600 ($19.96) and set a “buy” rating on the stock in a research note on Friday, November 29th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.53).

GSK Price Performance

Shares of LON:GSK opened at GBX 1,353.40 ($16.88) on Tuesday. The stock’s 50 day moving average is GBX 1,356.42 and its 200-day moving average is GBX 1,483.87. GSK has a twelve month low of GBX 1,282.50 ($16.00) and a twelve month high of GBX 1,823.50 ($22.75). The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. The firm has a market capitalization of £55.22 billion, a price-to-earnings ratio of 1,197.70, a PEG ratio of 1.24 and a beta of 0.31.

GSK Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be paid a dividend of GBX 15 ($0.19) per share. This represents a yield of 1.03%. The ex-dividend date is Thursday, November 14th. GSK’s dividend payout ratio (DPR) is presently 5,309.73%.

Insiders Place Their Bets

In other news, insider Jonathan Symonds acquired 1,500 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was purchased at an average price of GBX 1,315 ($16.40) per share, for a total transaction of £19,725 ($24,607.04). Insiders have bought 8,658 shares of company stock valued at $11,950,792 in the last three months. 1.61% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.